|Articles|June 29, 2018
Korean Biotech Talks About U.S. Company Launch
Author(s)Michelle Maskaly
Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
Advertisement
Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
He spoke to Pharm Exec during a company event in New York City.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection
2
Senate Democrats Expand Efforts to Expose Details of MFN Pharma Deals
3
When Ambition Meets Ambiguity: The Trends and Sentiments Shaping Biotech in 2026
4
JCA vs. Reality: Europe’s Push for Clinical Harmonization
5